Trials / Completed
CompletedNCT01376622
Changes in Pituitary Iron and Volume With Deferasirox
Changes in Pituitary Iron and Volume With Deferasirox in Transfusional Iron Overload
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 130 (actual)
- Sponsor
- Children's Hospital Los Angeles · Academic / Other
- Sex
- All
- Age
- 2 Years – 25 Years
- Healthy volunteers
- Accepted
Summary
Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands, particularly the pituitary gland, remains common in patients with transfusion dependent anemias. We would like to establish accurate population norms of pituitary R2 and volume and understand the progression of pituitary iron in transfused patients on Deferasirox.
Conditions
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2011-06-20
- Last updated
- 2023-10-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01376622. Inclusion in this directory is not an endorsement.